X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DIVIS LABORATORIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DIVIS LABORATORIES IPCA LABS/
DIVIS LABORATORIES
 
P/E (TTM) x 29.3 34.2 85.8% View Chart
P/BV x 4.3 7.5 57.4% View Chart
Dividend Yield % 0.1 0.6 18.2%  

Financials

 IPCA LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    IPCA LABS
Mar-18
DIVIS LABORATORIES
Mar-18
IPCA LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6951,142 60.9%   
Low Rs400533 75.0%   
Sales per share (Unadj.) Rs260.2146.6 177.5%  
Earnings per share (Unadj.) Rs19.033.0 57.4%  
Cash flow per share (Unadj.) Rs33.138.4 86.1%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.2 15.3%  
Book value per share (Unadj.) Rs213.0222.8 95.6%  
Shares outstanding (eoy) m126.20265.47 47.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.15.7 36.8%   
Avg P/E ratio x28.925.3 113.9%  
P/CF ratio (eoy) x16.621.8 76.0%  
Price / Book Value ratio x2.63.8 68.4%  
Dividend payout %5.330.3 17.4%   
Avg Mkt Cap Rs m69,120222,318 31.1%   
No. of employees `00013.310.8 123.2%   
Total wages/salary Rs m7,3594,561 161.4%   
Avg. sales/employee Rs Th2,477.43,616.0 68.5%   
Avg. wages/employee Rs Th555.2423.8 131.0%   
Avg. net profit/employee Rs Th180.6814.9 22.2%   
INCOME DATA
Net Sales Rs m32,83638,915 84.4%  
Other income Rs m4181,134 36.8%   
Total revenues Rs m33,25440,049 83.0%   
Gross profit Rs m4,50512,617 35.7%  
Depreciation Rs m1,7771,425 124.7%   
Interest Rs m24013 1,806.0%   
Profit before tax Rs m2,90512,313 23.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5113,543 14.4%   
Profit after tax Rs m2,3948,770 27.3%  
Gross profit margin %13.732.4 42.3%  
Effective tax rate %17.628.8 61.1%   
Net profit margin %7.322.5 32.4%  
BALANCE SHEET DATA
Current assets Rs m19,45545,351 42.9%   
Current liabilities Rs m10,0766,507 154.8%   
Net working cap to sales %28.699.8 28.6%  
Current ratio x1.97.0 27.7%  
Inventory Days Days98127 77.3%  
Debtors Days Days6795 70.4%  
Net fixed assets Rs m20,26021,160 95.7%   
Share capital Rs m252531 47.5%   
"Free" reserves Rs m26,63358,625 45.4%   
Net worth Rs m26,88659,156 45.4%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17367,832 60.7%  
Interest coverage x13.1926.8 1.4%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.6 139.0%   
Return on assets %6.412.9 49.4%  
Return on equity %8.914.8 60.1%  
Return on capital %10.820.8 51.7%  
Exports to sales %47.60-   
Imports to sales %14.921.8 68.2%   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,8848,485 57.6%   
Fx inflow Rs m15,64232,359 48.3%   
Fx outflow Rs m4,8849,042 54.0%   
Net fx Rs m10,75923,317 46.1%   
CASH FLOW
From Operations Rs m3,4117,759 44.0%  
From Investments Rs m-1,354-4,783 28.3%  
From Financial Activity Rs m-1,304-3,142 41.5%  
Net Cashflow Rs m753-166 -453.7%  

Share Holding

Indian Promoters % 45.9 52.0 88.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 11.8 96.6%  
FIIs % 25.3 19.0 133.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.2 101.2%  
Shareholders   36,892 31,796 116.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK  GSK PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 140 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets ended their day on a positive note today ahead of counting of Lok Sabha Election 2019 to be done tomorrow.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 22, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ALEMBIC PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS